Results 61 to 70 of about 12,771 (176)
Revista Brasileira de Hematologia e Hemoterapia, 2015 Objective: To evaluate trends in mortality among adults with myeloid leukemia in the Vale do Paraíba, State of São Paulo. Methods: Data from the Brazilian National Health Service database DATASUS provided the number of deaths caused by myeloid leukemia ...
Fernando Callera +2 more
doaj +1 more source
Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions
MedComm, Volume 7, Issue 3, March 2026.Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu +9 more
wiley +1 more source
Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2010 Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia.
Ćojbašić Irena +1 more
doaj +1 more source
Advances in Hematology, Volume 2026, Issue 1, 2026.Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) is a therapeutic challenge, particularly for elderly patients and those with comorbidities. While traditional intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is highly effective, therapy‐related toxicity and mortality is a ...
Lacey S. Williams +9 more
wiley +1 more source
BioMed Research International, Volume 2026, Issue 1, 2026.The cross‐reactivity of substrates, modulators with other enzymes significantly reduces/prevents our ability to design such highly specific, that is, “one warhead–one target”, modulators. On the other hand, the potential “impasse” fuels repurposing of already developed drugs.
Monika I. Konaklieva +2 more
wiley +1 more source
Folia Biologica, 2000 Several groups have shown that Ph-progenitors reappear in LTC of CML bone marrow or PBMNC when the cell preparations were derived from newly diagnosed Ph-positive patients or after induction chemotherapy. We have tested the hypothesis whether LTC may further decrease CML progenitors if the cells to be cultured were from IFN-treated
B, Schultheis +4 more
openaire +2 more sources
MedComm – Biomaterials and Applications, Volume 4, Issue 4, December 2025.This review highlights recent advances in MXene‐based electrochemiluminescence (ECL) biosensors, showcasing their exceptional sensitivity and versatility in detecting biomolecules, pathogens, and environmental pollutants. The integration of MXenes significantly enhances ECL signal amplification, paving the way for next‐generation diagnostic and ...
Kai Zhang
wiley +1 more source
The Concise Guide to PHARMACOLOGY 2025/26: Enzymes
British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +31 more
wiley +1 more source
Biologics: Targets & Therapy, 2016 Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous ...
Emole J, Talabi T, Pinilla-Ibarz J
doaj
Advanced Science, Volume 12, Issue 37, October 6, 2025.Cardiovascular disease (CVD) and cancer are leading causes of death worldwide, with overlapping risk factors and pathophysiological mechanisms. This review explores shared pathways, including metabolic dysregulation, chronic inflammation, and gut microbiome alterations, highlighting dual‐benefit strategies such as lifestyle modifications and repurposed
Shihan Xiang +6 more
wiley +1 more source